Almirall SA is a global biopharmaceutical company, which is focused on skin health. The company is headquartered in Barcelona, Barcelona and currently employs 2,084 full-time employees. The company went IPO on 2007-04-19. The firm focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The firm's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The firm operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Follow-Up Questions
Who is the CEO of Almirall SA?
Mr. Carlos Gallardo Pique is the Executive Chairman of the Board of Almirall SA, joining the firm since 2014.
What is the price performance of ALMRY stock?
The current price of ALMRY is $12.76, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Almirall SA?
Almirall SA belongs to Pharmaceuticals industry and the sector is Health Care
What is Almirall SA market cap?
Almirall SA's current market cap is $2.7B
Is Almirall SA a buy, sell, or hold?
According to wall street analysts, 15 analysts have made analyst ratings for Almirall SA, including 3 strong buy, 9 buy, 3 hold, 0 sell, and 3 strong sell
